Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 9, 2025

Brilliant Violet 421(TM) anti-mouse/human CD44

RRID:AB_10895752
Type: Antibody

Proper Citation

(BioLegend Cat# 103039, RRID:AB_10895752)

Antibody Information

URL: http://antibodyregistry.org/AB_10895752

Proper Citation: (BioLegend Cat# 103039, RRID:AB_10895752)

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC, ICC, IHC-P

Antibody Name: Brilliant Violet 421(TM) anti-mouse/human CD44

Description: This monoclonal targets CD44

Target Organism: mouse, human

Clone ID: Clone IM7

Antibody ID: AB_10895752

Vendor: BioLegend

Catalog Number: 103039

Alternative Catalog Numbers: 103040

Record Creation Time: 20231110T041903+0000

Record Last Update: 20241115T051643+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-mouse/human CD44.

No alerts have been found for Brilliant Violet 421(TM) anti-mouse/human CD44.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Sekiya T, et al. (2024) Tonic TCR and IL-1? signaling mediate phenotypic alterations of naive CD4+ T cells. Cell reports, 43(3), 113954.

Benguigui M, et al. (2024) Interferon-stimulated neutrophils as a predictor of immunotherapy response. Cancer cell, 42(2), 253.

Forcella P, et al. (2024) SAFB regulates hippocampal stem cell fate by targeting Drosha to destabilize Nfib mRNA. eLife, 13.

Nguele Meke F, et al. (2024) Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models. Cancer research communications, 4(1), 5.

Ingelshed K, et al. (2024) MDM2/MDMX inhibition by Sulanemadlin synergizes with anti-Programmed Death 1 immunotherapy in wild-type p53 tumors. iScience, 27(6), 109862.

Adamska JZ, et al. (2023) Ablation of Adar1 in myeloid cells imprints a global antiviral state in the lung and heightens early immunity against SARS-CoV-2. Cell reports, 42(1), 112038.

Shao TY, et al. (2023) Kruppel-like factor 2+ CD4 T cells avert microbiota-induced intestinal inflammation. Cell reports, 42(11), 113323.

Cohen GS, et al. (2023) Transplantation elicits a clonally diverse CD8+ T cell response that is comprised of potent CD43+ effectors. Cell reports, 42(8), 112993.

Freshour SL, et al. (2023) Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer. iScience, 26(10), 107937.

Yadavilli S, et al. (2023) Activating Inducible T-cell Costimulator Yields Antitumor Activity

Alone and in Combination with Anti-PD-1 Checkpoint Blockade. Cancer research communications, 3(8), 1564.

Ma S, et al. (2022) Heterochronic parabiosis induces stem cell revitalization and systemic rejuvenation across aged tissues. Cell stem cell, 29(6), 990.

Kurz E, et al. (2022) Exercise-induced engagement of the IL-15/IL-15R? axis promotes anti-tumor immunity in pancreatic cancer. Cancer cell, 40(7), 720.

Zebley CC, et al. (2021) Proinflammatory cytokines promote TET2-mediated DNA demethylation during CD8 T cell effector differentiation. Cell reports, 37(2), 109796.

Marangoni F, et al. (2021) Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. Cell, 184(15), 3998.

Cie?la M, et al. (2021) Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer. Molecular cell, 81(7), 1453.

Delacher M, et al. (2021) Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells. Immunity, 54(4), 702.

Kawakami R, et al. (2021) Distinct Foxp3 enhancer elements coordinate development, maintenance, and function of regulatory T cells. Immunity, 54(5), 947.

Frohner IE, et al. (2020) PP2AC Phospho-Tyr307 Antibodies Are Not Specific for this Modification but Are Sensitive to Other PP2AC Modifications Including Leu309 Methylation. Cell reports, 30(9), 3171.

Li Q, et al. (2018) E3 Ligase VHL Promotes Group 2 Innate Lymphoid Cell Maturation and Function via Glycolysis Inhibition and Induction of Interleukin-33 Receptor. Immunity, 48(2), 258.